Automate Your Wheel Strategy on CRDL
With Tiblio's Option Bot, you can configure your own wheel strategy including CRDL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CRDL
- Rev/Share 0.0
- Book/Share 0.3541
- PB 5.1055
- Debt/Equity 0.0064
- CurrentRatio 4.5177
- ROIC -1.217
- MktCap 149404804.7738
- FreeCF/Share -0.3591
- PFCF -5.9566
- PE -3.4422
- Debt/Assets 0.005
- DivYield 0
- ROE -2.0786
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CRDL | H.C. Wainwright | -- | Buy | -- | $9 | June 2, 2025 |
| Initiation | CRDL | Rodman & Renshaw | -- | Buy | -- | $7 | Jan. 28, 2025 |
News
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors
CRDL
Published: April 29, 2025 by: Newsfile Corp
Sentiment: Neutral
Published: April 29, 2025 by: Newsfile Corp
Sentiment: Neutral
Former Chief Medical Officer of Eli Lilly brings more than thirty years of pharmaceutical industry experience Toronto, Ontario--(Newsfile Corp. - April 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced that pharmaceutical industry veteran Timothy J. Garnett, M.D.
Read More
About Cardiol Therapeutics Inc. (CRDL)
- IPO Date 2019-01-15
- Website https://www.cardiolrx.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mr. David G. Elsley MBA
- Employees 18
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.